Fluid overload is a key cause of condition deterioration and hospital readmission in patients with heart failure and chronic kidney disease. There is a significant need for improved fluid monitoring in these chronic conditions to allow for early detection, intervention, reduced hospitalisation rates and improved patient outcomes.
One third of kidney failure patients are readmitted to hospital within 30 days after discharge. Half of heart failure patients are readmitted to hospital in the first six months after discharge The global chronic heart failure treatment devices market alone was estimated to be at $10 billion (USD) in 2015, and was projected to reach $14.8 billion (USD) in 2022. Chronic kidney disease (CKD) affects 10% of the population worldwide with Heart failure affecting at least 26 million people worldwide and is the primary reason for hospitalisation >65 years of age.
Osmetric is a simple low cost wearable that continuously monitors a patient’s fluid levels. Physicians can monitor a patient’s fluid levels remotely via the cloud. The platform provides continuous monitoring of patient fluid - no action is required by the patient. Osmetric is based on bioimpedance technology– estimations of fluid volume are based on their impedance to electrical flow.
Grey Innovation was commissioned by the Victorian Government to assess the innovation’s feasibility. Following the success of this study clinical studies for chronic kidney disease patients it is currently being tested in heart failure patients in Singapore and Australia.